MDA, MDMA and other mescaline-like substances in the US military’s search for a truth drug (1940s to 1960s)

Passie and colleagues situate their paper within a historiographical gap concerning the US military and intelligence services' experimental use of mescaline-like compounds (including TMA, MDA, MDE and MDMA) from the 1940s through the 1960s. Earlier work has documented experimentation with ‘‘truth drugs’’ such as scopolamine and mescaline, and a later focus on LSD, but relatively little detailed synthesis exists about the mescaline derivatives the US synthesised and tested for interrogation and behaviour‑manipulation purposes. The historical record is fragmented and partly secret, and the authors aim to assemble an overview from available documents, adding some previously unreported material where possible. The paper sets out to trace when and why these mescaline derivatives were produced and tested by US military and intelligence agencies, to describe the known laboratory and human experiments (including an account of a fatality at the New York State Psychiatric Institute), and to assess whether these compounds were ever used operationally. By reconstructing the chronology from German prehistory to postwar US programmes such as Project CHATTER and MKULTRA, the authors seek to clarify the rationale that guided interest in methylenedioxy and other mescaline‑like substances and to identify remaining uncertainties in the archival record.

The extracted text presents the work as a historical synthesis based on archival documents, contemporaneous reports and prior literature; however, it does not provide a formal methods section or a detailed search strategy. Passie and colleagues draw on a mixture of sources explicitly named in the narrative (for example, OSS and CIA memoranda, Army Chemical Corps records, NYSPI reports, the Army Inspector General report of 1975, and published experimental reports), but the selection criteria, databases or archives searched and the date coverage are not clearly reported in the extracted text. Where specific experimental or administrative records are discussed, the authors summarise content from animal toxicology reports, Edgewood Arsenal coding and correspondence, NYSPI clinical reports and legal/Inspector General findings. The approach is therefore a qualitative historical review that integrates primary and secondary materials into a chronological account rather than a systematic or quantitative meta‑analysis. Because the provenance and completeness of the source material are sometimes unclear or secret‑stamped, the authors periodically note where documentary gaps or redactions limit firm conclusions.

The narrative reconstructs a multi‑decade sequence of interest in ‘‘truth drugs’’. Early 20th‑century clinicians observed that scopolamine and barbiturates could produce states of disinhibition; parallel research on mescaline in Germany and the USA documented hallucinatory states and occasional reports of increased talkativeness. German wartime (Nazi) interrogation experiments with mescaline and other drugs were intercepted or later reported, and these activities fuelled Allied postwar interest. From the 1940s US efforts to find an interrogation‑useful pharmacological agent intensified. The OSS established a Truth Drug Committee in 1943 and trialled mescaline, barbiturates and Cannabis indica with limited success. The Navy ran Project CHATTER (late 1940s–early 1950s), and the CIA launched programs that evolved from BLUEBIRD and ARTICHOKE into MKULTRA (approved 1953), with explicit objectives to develop chemical agents capable of producing a reversible, non‑toxic aberrant mental state for use in eliciting information and manipulation. The Army Chemical Corps synthesised a series of mescaline derivatives (Edgewood Arsenal code numbers EA‑1304 to EA‑1322 are mentioned) and in November 1952 delivered several compounds to the New York State Psychiatric Institute (NYSPI) for human testing: MDPEA, MDA, MDE, DMA and DMMA among them. The extracted text emphasises that prior animal testing was minimal and limited to short LD50 determinations in mice, yet NYSPI investigators began human injections within a month of receipt. A central and detailed result reported is the death of Harold Blauer, a NYSPI patient treated for depression. Between December 1952 and January 1953 Blauer received a sequence of injections of mescaline derivatives; on 8 January 1953 he was given a fatal 450 mg injection of MDA. He developed tremor, seizure activity and coma and died despite resuscitative efforts. Official reports recorded an ‘‘unusual reaction’’ causing a coronary event; later investigations and legal review criticised inadequate animal toxicity testing and dosing decisions. A settlement of $18,000 was later paid to Blauer’s family. The authors describe subsequent secrecy around files, instructions to suppress disclosure, and the withholding of the fatality in NYSPI reports to the Chemical Corps. Following the Blauer fatality, the Army initiated more extensive animal toxicology studies (University of Michigan and related work). Behavioural and toxicity testing across species (mice, rats, guinea pigs, dogs and monkeys) found that methylenedioxy ring‑substituted compounds (MDA, MDOM, MDE, MDMA) showed higher toxicity compared with some other analogues; dogs were judged a more sensitive species for detecting hallucinogenic behavioural effects than rodents or monkeys. Structure–activity observations reported included decreased potency when the 5‑methoxy group was removed or by N‑demethylation, and increased potency after alpha‑substitution or introduction of a 3,4‑methylenedioxy group. Despite continuing secret work at NYSPI and other laboratories through the 1950s, the extracted text indicates a shift in official interest toward LSD because of its potency, and physical properties that favoured covert dissemination. LSD was used operationally in some circumstances in the mid‑1950s, but field and clinical experience made clear that information obtained under LSD and similar drugs was unreliable and that the drugs often induced severe anxiety, confusion or ‘‘freak‑outs’’. By the early 1960s interest in pharmacological ‘‘truth drugs’’ waned and interrogation paradigms shifted toward behavioural methods. The authors report that, while some methylenedioxy compounds were considered promising because they purportedly altered mood and reduced defences without grossly disrupting cognition, the archival record does not clearly show whether any of these derivatives were widely deployed operationally; some CIA staff stated ‘‘some concrete results’’ and the development of six products with limited operational use, but many relevant files were destroyed in 1960 and 1973, leaving the extent of field use uncertain.

Passie and colleagues interpret the assembled records as showing a recurrent pattern: serendipitous clinical observations prompted systematic interest in ‘‘truth drugs’’, but practical and ethical problems repeatedly curtailed operational adoption. Scopolamine and sedatives were rejected because they produced delirium, heavy sedation and impaired speech; mescaline and peyote induced distracting hallucinations. Early enthusiasm for LSD derived from its potency and physical characteristics, yet LSD likewise proved unreliable for eliciting valid information and caused severe adverse psychological reactions in some recipients. The authors characterise the Army’s mid‑century strategy as an effort to identify mescaline derivatives that would be potent enough for covert delivery, reduce unwanted hallucinatory effects, exert predictable effects across individuals and produce euphoria without subsequent ‘‘let‑down’’. Methylenedioxy compounds emerged as candidates because they seemed to lower anxiety and defensiveness while leaving cognition relatively intact, but animal toxicology flagged varying toxicity and the Blauer fatality highlighted the risks of inadequate preclinical testing and covert human experimentation. Key limitations the authors acknowledge are the fragmentary and often secret nature of archival material, incomplete documentation of post‑1953 NYSPI work, and the destruction or redaction of many CIA and military files, which prevents definitive statements about operational deployment. They note that while some internal CIA statements claim limited operational use of developed products, the available documents do not permit a clear reconstruction of which mescaline derivatives, if any, were used in the field. Finally, the authors place the historical arc in context: by the early 1960s pharmacological approaches to interrogation had largely been abandoned in favour of behavioural methods, reflecting accumulated evidence that tested drugs failed to meet the military’s stated operational criteria and presented unacceptable safety and validity problems. The discussion reiterates that uncertainty about the later human testing and operational use of mescaline derivatives remains because of secrecy and destroyed records.